Highly active and selective ligands for Integrin αvß6

The human integrin avß6, which is usually undetectable in normal adults’ cells, but highly upregulated in different types of cancer, is an emerging target for therapy as well as imaging across several common tumor types. However, only few ligands are known so far that are highly active for avß6 integrin and at the same time possess no binding affinity toward other RGD-recognizing integrins. Furthermore, their metabolic instability, their high molecular weight and the complexity of their structures limit their medical application.
This problem could now be solved by the present invention. The peptides according to the invention show a remarkable affinity for avß6 and high selectivity against other integrins.

Further information: PDF

Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0

Contact
Peer Biskup

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.